HomeSGEN • BMV
add
Seagen
Nakaraang pagsara
$3,711.48
Sakop ng taon
$3,711.48 - $3,711.48
Market cap
43.15B USD
P/E ratio
-
Dividend yield
-
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
(USD) | Set 2023info | Y/Y na pagbabago |
---|---|---|
Kita | 648.65M | 27.11% |
Gastos sa pagpapatakbo | 262.69M | 24.86% |
Net na kita | -215.79M | -13.09% |
Net profit margin | -33.27 | 11.02% |
Kita sa bawat share | -1.15 | -11.65% |
EBITDA | -209.33M | -19.47% |
Aktuwal na % ng binabayarang buwis | 0.26% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
(USD) | Set 2023info | Y/Y na pagbabago |
---|---|---|
Cash at mga panandaliang investment | 1.24B | -29.86% |
Kabuuang asset | 3.63B | 0.42% |
Kabuuang sagutin | 1.08B | 35.94% |
Kabuuang equity | 2.55B | — |
Natitirang share | 188.66M | — |
Presyo para makapag-book | 274.52 | — |
Return on assets | -16.01% | — |
Return on capital | -21.12% | — |
Cash Flow
Net change in cash
(USD) | Set 2023info | Y/Y na pagbabago |
---|---|---|
Net na kita | -215.79M | -13.09% |
Cash mula sa mga operasyon | -35.82M | 58.21% |
Cash mula sa pag-invest | 142.49M | 119.31% |
Cash mula sa financing | 15.52M | -15.59% |
Net change in cash | 119.90M | 1,958.05% |
Malayang cash flow | 71.52M | 1,141.10% |
Tungkol
Seagen Inc. is an American biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. The company, headquartered in Bothell, Washington, is the industry leader in antibody-drug conjugates or ADCs, a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Antibody-drug conjugates are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.
The company's flagship product Adcetris is commercially available for four indications in more than 65 countries, including the U.S., Canada, Japan and members of the European Union.
To expand on the clinical opportunities of brentuximab vedotin, Seattle Genetics is conducting a broad clinical development program
to evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings. The company is jointly developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company. Wikipedia
Itinatag
Hul 15, 1997
Headquarters
Website
Mga Empleyado
3,256